# US 2023/0265156 A1 · Immunogenic cd1d binding peptides > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2023/0265156 A1 - Document ID: US20230265156A1 - Status: Published application - Kind: A1 - Application number: 17/934,607 - Filed: 2022-09-23 - Published: 2023-08-24 - Earliest claimed: 2016-04-19 - Assignees: Imcyse SA - Applicants: Imcyse SA - Inventors: Luc VANDER ELST - Web page: https://patentgrep.com/patent/US20230265156A1 ## CPC - C07K 14/70539: {MHC-molecules, e.g. HLA-molecules} - A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance} - A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells - A61K 40/22: Immunosuppressive or immunotolerising - A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance} - A61K 40/42: Cancer antigens - A61P 35/00: Antineoplastic agents - A61P 37/02: Immunomodulators - A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection - A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) - A61K 2039/55505: {Inorganic adjuvants} - A61K 2239/38: characterised by the dose, timing or administration schedule - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The invention relates to isolated immunogenic peptides comprising a CD1d binding peptide, and immediately adjacent or separated from said CD1d binding peptide, a redox motif sequence which is further flanked by a histidine or tryptophan amino acids. The invention further relates to these peptides for use as a medicament The invention further relates to methods wherein these peptides are used for generating NKT cells which are cytolytic against cells presenting the cognate antigen. ## Claims ### Claim at position 1 1-15. (canceled) ### Claim 16 A method of treating an allergic disorder or autoimmune disease in a subject, comprising the step of administering to said subject an effective amount of a fusion peptide of between 12 and 100 amino acids wherein said fusion peptide comprises: (i) a first peptide of an antigen comprising the [FWYH]-X(2)-[VILM]-X(2)-[FWYH] (SEQ ID NO: 61) first sequence motif, wherein the antigen is myelin oligodendrocyte glycoprotein (MOG), and (ii) a [HW]-X(0,2)-C-X(2)-C ((SEQ ID NO: 7), (SEQ ID NO: 8), (SEQ ID NO: 9)) or C-X(2)-C-X(0,2)-[HW] ((SEQ ID NO: 10), (SEQ ID NO: 11), (SEQ ID NO: 12)) redox motif sequence, which is immediately adjacent or separated by at most 7 amino acids from said first sequence motif. ### Claim 17 (depends on 16) The method according to claim 16, wherein the redox motif sequence is located N terminally from the first sequence motif within the fusion peptide. ### Claim 18 (depends on 16) The method according to claim 16, wherein the redox motif sequence is located C terminally from the first sequence motif within the fusion peptide. ### Claim 19 (depends on 16) The method according to claim 16, wherein said fusion peptide has a length of between 12 and 50 amino acids. ### Claim 20 (depends on 16) The peptide according to claim 16, wherein the first peptide of the antigen comprises the [FWY]-X(2)-[VILM]-X(2)-[FWY] (SEQ ID NO:63). ### Claim 21 (depends on 16) The method according to claim 16, wherein the redox motif is [HW]-C-X(2)-[CST] (SEQ ID NO: 1) or [CST]-X(2)-C-[HW] (SEQ ID NO:4). ### Claim 22 (depends on 16) The method according to claim 16, wherein the redox motif sequence is [HW]-C-X(2)-C (SEQ ID NO: 7) or C-X(2)-C-[HW] (SEQ ID NO: 10). ### Claim 23 (depends on 16) The method according to claim 16, wherein the redox motif sequence is H-C-X(2)-[CST] (SEQ ID NO: 101) or [CST]-X(2)-C-H (SEQ ID NO: 102). ### Claim 24 (depends on 16) The method according to claim 16, wherein the redox motif sequence is H-C-X(2)-C (SEQ ID NO: 48) or C-X(2)-C-H (SEQ ID NO: 42). ### Claim 25 (depends on 16) The method according to claim 16, wherein said first peptide comprises the amino acid sequence FLRVPCWKI (SEQ ID NO: 103). ### Claim 26 (depends on 1) The method according to claim 1, wherein said fusion peptide comprises the sequence of HCGPCGGFLRVPCWKI (SEQ ID NO: 87), WCGPCGGFLRVPCWKI (SEQ ID NO: 88), HCHGCGGFLRVPCWKI (SEQ ID NO: 105), or WCHGCGGFLRVPCWKI (SEQ ID NO: 106). ### Claim 27 (depends on 16) The method according to claim 16, wherein the allergic disorder or autoimmune disease is the autoimmune disease multiple sclerosis. ### Claim 28 A method of treating an allergic disorder or autoimmune disease in a subject, comprising the step of administering to said subject an effective amount of a population NKT cells which are cytolytic against cells presenting an antigen obtained by in vitro contacting peripheral blood cells with a fusion peptide of between 12 and 100 amino acids wherein said fusion peptide comprises: (i) a first peptide of the antigen comprising the [FWYH]-X(2)-[VILM]-X(2)-[FWYH] (SEQ ID NO: 61) first sequence motif, wherein the antigen is myelin oligodendrocyte glycoprotein (MOG), and (ii) a [HW]-X(0,2)-C-X(2)-C ((SEQ ID NO: 7), (SEQ ID NO: 8), (SEQ ID NO: 9)) or C-X(2)-C-X(0,2)-[HW] ((SEQ ID NO: 10), (SEQ ID NO: 11), (SEQ ID NO: 12)) redox motif sequence, which is immediately adjacent or separated by at most 7 amino acids from said first sequence motif expanding said cells in the presence of interleukin 2.